New triple therapy aims to stop kidney cancer from spreading further

NCT ID NCT06601296

First seen Nov 12, 2025 · Last updated May 13, 2026 · Updated 19 times

Summary

This study tests whether adding a drug that wakes up the immune system (IMSA101) and precise radiation (PULSAR) to standard immunotherapy can control metastatic kidney cancer that has started to grow in a few spots. About 15 adults with clear cell kidney cancer that has spread and is progressing in up to 5 places will receive the combination. The goal is to see if this approach can delay the need for stronger treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC RENAL CELL CARCINOMA (MRCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Texas Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.